Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...

The following is a summary of “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis,” published in the November ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

"It's been interesting to watch her trend down the growth chart to being a kid without obesity," she said. As optimism for ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also ...

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related hospitalisations. Read more!